首页 > 市场调查报告书 > 製药

生物製剂分子标靶治疗学

北美抗体药物偶联物市场预测至 2030 年 - 区域分析 - 按技术、应用和配销通路

市场调查报告书

商品编码

1481965

北美抗体药物偶联物市场预测至 2030 年 - 区域分析 - 按技术、应用和配销通路

North America Antibody Drug Conjugates Market Forecast to 2030 - Regional Analysis - By Technology, Application, and Distribution Channel

出版日期: 2024年03月04日 | 出版商:

The Insight Partners | 英文 100 Pages | 订单完成后即时交付

价格

简介目录图表

2022年北美抗体药物偶联物市值为36.5981亿美元，预计2030年将达到136.8158亿美元；预计2022年至2030年复合年增长率为17.9%。

FDA 对 ADC 的批准不断增加，推动了北美抗体药物偶联物市场的发展

根据2021 年9 月发表在美国国家医学图书馆的一篇文章《An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy for Cancer Therapy》，2017 年ADC 批准数量为8 个，2021 年9 月增加至11个。这些公司主要针对血癌和其他癌症类型，如肺癌、膀胱癌和妇科肿瘤。此外，2021年6月，美国投资银行Evercore和Evercore ISI预计，到2030年，两家公司每年的ADC销售额将超过200亿美元。 ADC 的批准和商业化不断增加，导致市场显着成长。以下是 FDA 批准的 ADC 清单。

表 1. FDA 核准的 ADC 列表

序号公司商品名称 ADC 药物癌症类型核准年份

1 辉瑞/惠氏 Mylotarg Gemtuzumab ozogamicin 復发性急性髓性白血病 (AML) 2000； 2017年

2 Seagen Genetics，Millennium/Takeda Adcetris Brentuximab vedotin 復发 HL 与復发 sALCL 2011

3 基因泰克、罗氏 Kadcyla 曲妥珠单抗 emtansine HER2 阳性转移性乳癌 (mBC) 2013

4 辉瑞/惠氏 Besponsa Inotuzumab ozogamicin 復发或难治性 CD22 阳性 B 细胞前驱急性淋巴母细胞白血病2017

5 阿斯特捷利康 Lumoxiti Moxetumomab pasudotox 成人復发或难治性毛细胞白血病 (HCL) 2018

6 基因泰克、罗氏 Polivy Polatuzumab vedotin-piiq 復发或难治性瀰漫性大 B 细胞淋巴瘤 (DLBCL) 2019

7 Astellas/Seagen Genetics Padcev Enfortumab vedotin 接受 PD-1 或 PD-L1 抑制剂以及含 Pt 治疗的成人转移性尿路上皮癌 2019

8 阿斯利康/第一三共 Enhertu 曲妥珠单抗 deruxtecan 成人转移性 HER2 阳性乳癌，既往接受过两种或多种抗 HER2 治疗方案 2019

9 免疫医学 Trodelvy Sacituzumab govitecan 成人转移性三阴性乳癌 (mTNBC)，以及接受过至少两种先前治疗的復发或难治性转移性疾病患者 2020

10 葛兰素史克 (GSK) Blenrep Belantamab mafodotin-blmf 2020 年成人復发或难治性多发性骨髓瘤，于 2022 年 11 月 22 日在美国撤回。

11 ADC 疗法 Zynlonta Loncastuximab tesirine-lpyl 大 B 细胞淋巴瘤 2021

12 Seagen Inc Tivdak Tisotumab vedotin-tftv 復发性或转移性子宫颈癌 2021

13 ImmunoGen Elahere Mirvetuximab soravtansine 铂金抗药性卵巢癌 2022

北美抗体药物偶联物市场概况

基于美国、加拿大和墨西哥对北美抗体药物偶联物（ADC）市场进行了分析。该地区的市场成长归因于 ADC 研发的增加、产品批准的增加、对 ADC 认识的提高以及营运商之间合併、合作和伙伴关係数量的增加。此外，癌症发生率的显着增加是对 ADC 需求增加的其他主要因素之一。

此外，公司之间不断加强合作以在不同地区扩展其技术，从而促进市场成长。 2023 年 8 月，ImmunoGen, Inc. 和武田製药有限公司在日本合作开发和商业化 ELAHERE（免疫原 ADC 疗法）。根据合作协议，ImmunoGen, Inc. 在获得 FDA 加速批准 ELAHERE 用于治疗铂类抗药性卵巢癌后将获得预付款和额外付款。如果武田透过ELAHERE 在日本的净销售额实现了某些监管和商业里程碑以及两位数的特许权使用费，它将向ImmunoGen, Inc.支付额外款项。并将供应该产品进行开发和销售。作为回报，武田将负责所有监管备案，并拥有在日本开发和商业化 ELAHERE 的独家许可。

北美抗体药物偶联物市场收入及 2030 年预测（百万美元）

北美抗体药物偶联物市场细分

北美抗体药物偶联物市场根据技术、应用、配销通路和国家进行细分。

基于技术，北美抗体药物偶联物市场抗体药物偶联物市场分为可裂解接头和不可裂解接头。 2022 年，可裂解连接子部分占据了更大的份额。

根据应用，北美抗体药物偶联物市场抗体药物偶联物市场分为血癌、乳癌、卵巢癌、尿路上皮癌等。 2022 年，乳癌细分市场所占比重最大。

根据配销通路，北美抗体药物偶联物市场抗体药物偶联物市场分为医院药房、零售药房和线上药房。 2022年，医院药局部门占最大份额。

根据国家/地区，北美抗体药物偶联物市场分为美国、加拿大和墨西哥。 2022年，美国主导北美抗体药物偶联物市场。

ADC Therapeutics SA、辉瑞公司、罗氏公司、ImmunoGen 公司、葛兰素史克公司、吉利德科学公司、阿斯利康公司、安斯泰来製药公司、荣昌生物有限公司和武田製药有限公司是在北方运营的一些领先公司美国抗体药物偶联物市场。

According to an article, An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy, published in the National Library of Medicine in September 2021, there were eight approvals for ADC in 2017, and it increased to 11 in September 2021. The FDA has approved a few more ADCs, including Lumoxiti, till the end of November 2022. Worldwide, more than 50 biopharmaceutical companies are involved in developing ADCs. The companies have targeted mainly blood cancer and other cancer types, such as lung, bladder, and gynecological tumors. Additionally, in June 2021, Evercore, a US-based Investment Banking and Evercore ISI, estimated that by 2030, the companies will sell ADCs for over US$ 20 billion annually. The increasing approvals and commercialization of ADCs are leading to significant market growth. Below is a list of FDA-approved ADCs.

Table 1. List of FDA-Approved ADCs

Sr. No. Company Trade Name ADC Drug Cancer Type Approval Year

1 Pfizer/Wyeth Mylotarg Gemtuzumab ozogamicin Relapsed Acute Myelogenous Leukemia (AML) 2000; 2017

2 Seagen Genetics, Millennium/Takeda Adcetris Brentuximab vedotin Relapsed HL and Relapsed sALCL 2011

3 Genentech, Roche Kadcyla Trastuzumab emtansine HER2-positive Metastatic Breast Cancer (mBC) 2013

4 Pfizer/Wyeth Besponsa Inotuzumab ozogamicin Relapsed or Refractory CD22-positive B-cell Precursor Acute Lymphoblastic Leukemia 2017

5 Astrazeneca Lumoxiti Moxetumomab pasudotox Relapsed or refractory hairy cell leukaemia (HCL) in adults 2018

6 Genentech, Roche Polivy Polatuzumab vedotin-piiq Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) 2019

7 Astellas/Seagen Genetics Padcev Enfortumab vedotin Metastatic urothelial cancer in adult who have received a PD-1 or PD-L1 inhibitor, and a Pt-containing therapy 2019

8 AstraZeneca/Daiichi Sankyo Enhertu Trastuzumab deruxtecan Metastatic HER2-positive breast cancer in adults, received two or more prior anti-HER2 based regimens 2019

9 Immunomedics Trodelvy Sacituzumab govitecan Metastatic triple-negative breast cancer (mTNBC) in adults, and patients received minimum two prior therapies for patients with relapsed or refractory metastatic disease 2020

10 GlaxoSmithKline (GSK) Blenrep Belantamab mafodotin-blmf Relapsed or refractory multiple myeloma in adults 2020, withdrawn on 22 Nov. 2022 in the US.

11 ADC Therapeutics Zynlonta Loncastuximab tesirine-lpyl Large B-cell lymphoma 2021

12 Seagen Inc Tivdak Tisotumab vedotin-tftv Recurrent or metastatic cervical cancer 2021

13 ImmunoGen Elahere Mirvetuximab soravtansine Platinum-resistant ovarian cancer 2022

North America Antibody Drug Conjugates Market Overview

The antibody drug conjugates (ADCs) market in North America is analyzed based on the US, Canada, and Mexico. The market growth in the region is attributed to increasing research and development for ADCs, rising product approvals, growing awareness about ADCs, and rising number of mergers, collaborations, and partnerships among the operating players. In addition, significantly growing incidences of cancer are among the other leading factors escalating the demand for ADCs.

Furthermore, growing partnerships among the companies to expand their technologies in different regions enable market growth. In August 2023, ImmunoGen, Inc. and Takeda Pharmaceutical Company Limited collaborated to develop and commercialize ELAHERE, Immunogens ADC therapy, in Japan. Under the collaboration agreement, ImmunoGen, Inc. receives upfront and additional payments upon conversion of FDA accelerated approval of ELAHERE to treat platinum-resistant ovarian cancer. If Takeda achieves certain regulatory and commercial milestones and double-digit royalties through the net sales of ELAHERE in Japan, it will pay an additional payment to ImmunoGen, Inc. Nevertheless, Immunogen has retained its exclusive production rights and will supply the product for development and commercialization in Japan. In return, Takeda will be responsible for all regulatory filing and have an exclusive license to develop and commercialize ELAHERE in Japan.

North America Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Million)

North America Antibody Drug Conjugates Market Segmentation

The North America antibody drug conjugates market is segmented based on technology, application, distribution channel, and country.

Based on technology, the North America antibody drug conjugates market antibody drug conjugates market is bifurcated into cleavable linker and non-cleavable linker. The cleavable linker segment held a larger share in 2022.

Based on application, the North America antibody drug conjugates market antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. The breast cancer segment held the largest share in 2022.

Based on distribution channel, the North America antibody drug conjugates market antibody drug conjugates market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share in 2022.

Based on country, the North America antibody drug conjugates market is categorized into US, Canada, and Mexico. The US dominated the North America antibody drug conjugates market in 2022.

ADC Therapeutics SA, Pfizer Inc, Hoffmann-La Roche Ltd, ImmunoGen, Inc, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, RemeGen Co Ltd, and Takeda Pharmaceutical Co Ltd are some of the leading companies operating in the North America antibody drug conjugates market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Market Attractiveness

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Antibody Drug Conjugates Market - Key Industry Dynamics

4.1 Key Market Drivers:
- 4.1.1 Growing Strategic Partnerships to Develop Antibody Drug Conjugates
- 4.1.2 Rising Incidences of Cancer Cases
- 4.1.3 Increasing FDA Approvals for ADCs
4.2 Market Restraints
- 4.2.1 High Cost of ADCs Development and Commercialization
4.3 Market Opportunities
- 4.3.1 Increasing Investments to Develop ADCs
4.4 Market Trends
- 4.4.1 Escalating Pipeline of ADCs
4.5 Impact Analysis:

5. Antibody Drug Conjugates Market - North America Market Analysis

5.1 North America Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030

6. North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Technology

6.1 Overview
6.2 North America Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
6.3 Cleavable Linker
- 6.3.1 Overview
- 6.3.2 Cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Non-cleavable Linker
- 6.4.1 Overview
- 6.4.2 Non-cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Application

7.1 Overview
7.2 North America Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Blood Cancer
- 7.3.1 Overview
- 7.3.2 Blood Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Breast Cancer
- 7.4.1 Overview
- 7.4.2 Breast Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Ovarian Cancer
- 7.5.1 Overview
- 7.5.2 Ovarian Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Urothelial Cancer
- 7.6.1 Overview
- 7.6.2 Urothelial Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
- 7.7.1 Overview
- 7.7.2 Others: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Distribution Channel

8.1 Overview
8.2 North America Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacies
- 8.3.1 Overview
- 8.3.2 Hospital Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacies
- 8.4.1 Overview
- 8.4.2 Retail Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
- 8.5.1 Overview
- 8.5.2 Online Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Antibody Drug Conjugates Market - Country Analysis

9.1 North America Antibody Drug Conjugates Market, Revenue and Forecast To 2030
- 9.1.1 Overview
- 9.1.2 North America Antibody Drug Conjugates Market Breakdown, by Country Revenue (2022) (US$ Million)
- 9.1.3 North America: Antibody Drug Conjugates Market, by Countries,2022 and 2030 (%)
  - 9.1.3.1 US
    - 9.1.3.1.1 Overview
    - 9.1.3.1.2 US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.1.3 US: Antibody Drug Conjugates Market, by Technology
    - 9.1.3.1.4 US: Antibody Drug Conjugates Market, by Application
    - 9.1.3.1.5 US: Antibody Drug Conjugates Market, by Distribution Channel
  - 9.1.3.2 Canada
    - 9.1.3.2.1 Overview
    - 9.1.3.2.2 Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.2.3 Canada: Antibody Drug Conjugates Market, by Technology
    - 9.1.3.2.4 Canada: Antibody Drug Conjugates Market, by Application
    - 9.1.3.2.5 Canada: Antibody Drug Conjugates Market, by Distribution Channel
  - 9.1.3.3 Mexico
    - 9.1.3.3.1 Overview
    - 9.1.3.3.2 Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.3.3 Mexico: Antibody Drug Conjugates Market, by Technology
    - 9.1.3.3.4 Mexico: Antibody Drug Conjugates Market, by Application
    - 9.1.3.3.5 Mexico: Antibody Drug Conjugates Market, by Distribution Channel

10. Antibody Drug Conjugates Market-Industry Landscape

10.1 Overview
10.2 Organic Growth Strategies
- 10.2.1 Overview
10.3 Inorganic Growth Strategies
- 10.3.1 Overview
10.4 Companies' Manufacturing Capacities and Capabilities

11. Company Profiles

11.1 ADC Therapeutics SA
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Pfizer Inc
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Hoffmann-La Roche Ltd
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 ImmunoGen, Inc.
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 GSK Plc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Gilead Sciences Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 AstraZeneca Plc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Astellas Pharma Inc
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 RemeGen Co Ltd
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 Takeda Pharmaceutical Co Ltd
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms

简介目录图表

List Of Tables

Table 1. North America Antibody Drug Conjugates Market Segmentation
Table 2. New Cancer Cases Worldwide, in 2020
Table 3. List of FDA-Approved ADCs
Table 4. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 5. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 6. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 7. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 8. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 9. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 10. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 11. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 12. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 13. Recent Organic Growth Strategies in Antibody Drug Conjugates Market
Table 14. Recent Inorganic Growth Strategies in the Antibody Drug Conjugates Market
Table 15. Glossary of Terms, Antibody Drug Conjugates Market

List Of Figures

Figure 1. North America Antibody Drug Conjugates Market Segmentation, By Country
Figure 2. Key Insights
Figure 3. North America Antibody Drug Conjugates Market - Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. North America Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030
Figure 6. North America Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
Figure 7. Cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Non-Cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. North America Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
Figure 10. Blood Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Breast Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Ovarian Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Urothelial Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. North America Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 16. Hospital Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Retail Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Online Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. North America Antibody Drug Conjugates, by Key Country - Revenue (2022) (US$ Million)
Figure 20. North America: Antibody Drug Conjugates Market, By Key Countries, 2022 and 2030 (%)
Figure 21. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

02-2729-4219

+886-2-2729-4219

License/价格